Michael May is president and CEO of the Centre for Commercialization of Regenerative Medicine (CCRM), a Canadian not-for-profit that develops technologies and launches new companies by supporting both academic and industry activities in the field of regenerative medicine, including cell and gene therapy. With a staff of 70, a network of academic members, 50+ industry partners, dedicated funding, and facilities to develop technologies, manufacture cell product and incubate companies, CCRM is generating health and economic benefits for its stakeholders. Prior to CCRM, Michael was the president and cofounder of Rimon Therapeutics Ltd., a Toronto-based tissue engineering company developing novel medical polymers that possess drug-like activity.
Dr. May sits on a number of boards and advisory committees including: MaRS Innovation; the Centre for the Commercialization of Antibodies and Biologics (CCAB); the Entrepreneurship Leadership Council at the University of Toronto; the To Health! Human & Science Steering Committee; the Cell and Gene Therapy Insights, Editorial Advisory Board; the Industry Committee of the International Society for Stem Cell Research (ISSCR); and the Executive Committee, Alliance for Regenerative Medicine (ARM). He is the chair of several startup companies, including ExCellThera and PanCELLa. Dr. May completed his PhD in Chemical Engineering at the University of Toronto in 1998 as an NSERC Scholar and was awarded the Martin Walmsley Fellowship for Technological Entrepreneurship.